Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027

Cartesian Therapeutics, Inc.

Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.
Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.
CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.
Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.
Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027.

item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #5 for 2026-05-26. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-26-000087
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2026-05-26T11:08:51+00:00
discovered_at: 2026-05-26T11:10:00.237897+00:00
generated_at: 2026-05-26T11:12:52.292203+00:00
sec_items: ["1.01", "2.03", "3.02", "5.02", "7.01", "9.01"]
event_type: debt
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-26-000087
json_url: https://secwatch.observer/filing/0001453687-26-000087.json
markdown_url: https://secwatch.observer/filing/0001453687-26-000087.md
text_url: https://secwatch.observer/filing/0001453687-26-000087.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/0001453687-26-000087-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnac-20260522.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Milos Miljkovic

Chief Medical Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2026-05-31
Filed: May 26, 2026 11:08 UTC

On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.

Source-grounded claims

0b672e6ba1

Milos Miljkovic resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..

On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0001453687-26-000087

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.